



ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: www.americasblood.org

2026 #8

March 16, 2026

INSIDE:

CBER Director Leaving Agency in April2

REGULATORY NEWS....2

WORD IN WASHINGTON3

PEOPLE.....4

LAST CALL: Register for Part 3 of the ADRP Webinar Series on Planning,5

Supplementing, and Maximizing Staffing and Production5

Schedule Released for 2026 ADRP Annual Conference – Register Today!5

Volunteer to Join An ADRP Committee in 2026!5

ADRP Trends in Donor Relations Study Is Now Open.....6

MEMBER NEWS.....6

GLOBAL NEWS6

ADVANCED THERAPIES NEWS.....7

COMPANY NEWS8

CALENDAR.....9

POSITIONS.....9

Please Note: The ABC Newsletter will not be published on Mar. 23rd. We will resume regular publication on Monday, Mar. 30th. Thank you for your continued interest.

ABC Releases 2026 Advocacy Agenda

America’s Blood Centers (ABC) recently announced its [2026 Advocacy Agenda](#) to more than 200 attendees and industry partners during the 2026 ABC Annual Meeting in Tucson, Ariz., ABC’s highest-attended Annual Meeting to date. The Advocacy Agenda includes the federal legislative and regulatory priorities that are most important to community blood centers and features clearly defined solutions that have been developed in consultation with the ABC Board of Directors, Policy Council, and input from member blood centers. It will guide the work of the association on behalf of its member blood centers as ABC continues to urge the Trump Administration, Congress, and industry stakeholders to promote the value of blood to patients, communities, and the healthcare system by:

- “supporting the bipartisan [BLOOD Centers Act](#) (H.R. 5791), which would require the U.S. Food and Drug Administration (FDA) to modernize and streamline the licensure process and urges the FDA to update the licensure process to allow blood centers to quickly and safely meet the changing demands for blood components for patients;
- updating the payment policy for federal insurance programs to provide sufficient reimbursement to allow for broader adoption of prehospital blood transfusions;
- strengthening the cyber resilience of the blood community by providing increased support and resources for blood centers to update their current information technology infrastructures and bolstering their ability to prevent potential attacks;
- supporting a robust donor base by prioritizing blood donation as a national imperative;
- committing federal resources in support of the vital role of blood in the healthcare system; and
- reducing unnecessary and burdensome regulation to support innovation and blood product availability.”

ABC thanks its member blood centers and partners who have and continue to help advance the priorities and work of independent community blood centers. We will continue to provide updates and additional information regarding the 2026 Advocacy Agenda and our advocacy efforts as they become available and encourage you to mark your calendar to join us in Washington, D.C. for the 2026 Advocacy Workshop June 8th-9th. Please [contact us](#) with questions or requests for additional information. 💧

CBER Director Leaving Agency in April



U.S. Food and Drug Administration (FDA) Commissioner Martin Makary, MD, MPH has [announced](#) that Vinay Prasad, MD, MPH will leave his roles as director of the FDA's Center for Biologics Evaluation and Research (CBER) and Chief Medical and Scientific Officer of FDA at the end of April. In a post on X, Commissioner Makary explained that, "[a] year ago, Dr. Prasad came to the FDA to implement four major long-lasting reforms: 2-to-1 pivotal trial requirement, national priority reviews, a risk-stratified COVID-19 vaccine framework, and the new plausible mechanism framework for ultra rare diseases which we launched last week. Also, under his leadership, his center hit a record number of approvals in December 2025. He got a tremendous amount accomplished within his one-year sabbatical from the University of California (San Francisco) and will be returning back to his academic home later next month. We will name a successor before his departure. I want to thank him for his service and personal sacrifice to take time away from his family." Dr. Prasad joined FDA in May 2025 and previously resigned from the agency in July 2025 before returning in August 2025.

(Source: FDA Commissioner Martin Makary, MD, MPH [X Post](#), 3/6/26) 

REGULATORY NEWS

The U.S. Food and Drug Administration (FDA) has [published](#) a March 9th notice in the *Federal Register* titled "Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry; Availability." The notice explains that the guidance is, "intended for foreign and domestic human and animal drug manufacturing establishments inspected by FDA whose drugs are regulated by the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), and the Center for Veterinary Medicine (CVM). The purpose of [the guidance] is to assist manufacturers who choose to respond to FDA when they receive an FDA Form 483 Inspectional Observations (FDA 483) at the conclusion of a drug inspection to assess conformity with current good manufacturing practice (CGMP) requirements." Comments are due by May 8th.

(Source: *Federal Register* [Notice](#), 3/9/26)

(continued on page 3)

The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2026 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry
 Chief Medical Officer: Jed Gorlin
 Editor: Mack Benton
 Subscriptions Manager: Leslie Maundy
Annual Subscription Rate: \$420

Send subscription queries to memberservices@americasblood.org
 America's Blood Centers
 1717 K St. NW, Suite 900, Washington, DC 20006
 Phone: (202) 393-5725
 Send news tips to newsletter@americasblood.org.

REGULATORY NEWS (continued from page 2)

The FDA CBER has published an [updated version](#) of SOPP 8401.2: **Administrative Processing of BLA and NDA Supplements on March 10th**. The document aims to serve as a Standard Operating Policy and Procedure (SOPP) guide, “for CBER staff on the administrative processing of supplements to Biologics License Application (BLAs) and New Drug Application (NDAs). This SOPP applies to supplements processed by CBER including those subject to the Prescription Drug User Fee Act (PDUFA) and the Biosimilar User Fee Act (BsUFA). This SOPP does not apply to supplements for medical device BLAs or those subject to the Generic Drug User Fee Act (GDUFA).”

(Source: FDA [Announcement](#), 3/10/26) 💧

WORD IN WASHINGTON

The U.S. Department of Health and Human Services (HHS) issued a [communication](#) on March 13th urging “the Healthcare and Public Health (HPH) Sector to Strengthen Cyber Defenses Amid Elevated Threats.” Specifically, the email explained that the sectors should, “remain vigilant against elevated cyber threat actor risks. As demonstrated during previous periods of increased geopolitical tensions, state-sponsored and state-aligned cyber actors may increase their targeting of U.S. critical infrastructure. [HHS encourages] all HPH organizations to leverage the HPH [Cybersecurity Performance Goals](#) (CPGs) as they work to fortify their defenses.” Actions that organizations can take include:

- “[e]stablish network micro-segmentation security to minimize the attack surface by dividing networks into finely controlled segments;
- [r]efrain from directly connecting medical equipment and operational technology (OT)/industrial control system (ICS) assets to the public internet. If remote access is required, enforce deny-by-default allow lists;
- [c]hange default passwords, particularly on internet of things (IOT) and medical devices as soon as possible;
- [i]mplement phishing-resistant multi-factor authentication (MFA);
- [p]atch all systems against [known exploited vulnerabilities](#) and leverage available alerting from HHS and CISA;
- [c]onsider using the new [Cybersecurity Module within the HHS RISC 2.0 Tool](#) to assess cyber risk and prioritize critical mitigation approaches. You may also leverage the Cybersecurity and Infrastructure Security Agency’s (CISA) free [cyber hygiene services](#);
- [b]e vigilant of Distributed Denial-of-Service Campaigns: Targeted distributed denial-of-service campaigns against public-facing services and websites intended to degrade availability and create cascading impacts, particularly when traffic filtering and rate-limiting protections are absent or insufficient. For additional information, please review CISA’s document on [Understanding and Responding to Distributed Denial-Of-Service Attacks](#);
- [o]rganizations are encouraged to remind users to remain vigilant as phishing campaigns often increase during periods of heightened global conflict and uncertainty. Threat actors frequently exploit current events to craft convincing emails, messages, and websites designed to trick users into revealing credentials or clicking malicious links. Users should exercise extra caution when reviewing unexpected communications, especially those that create a sense of urgency or reference ongoing conflicts. Reinforcing basic cyber hygiene — such as verifying the sender, avoiding suspicious links or attachments, and reporting potential phishing attempts promptly — can help reduce the risk of compromise during this period; and
- [r]eview and rehearse incident response plans.”

(HHS [Communication](#), 3/13/26)

(continued on page 4)

WORD IN WASHINGTON (continued from page 3)

The Administration for Strategic Preparedness and Response (ASPR), a division of HHS, has [re-leased](#) a new “cybersecurity module within the [Risk Identification and Site Criticality \(RISC\) 2.0 Toolkit](#).” A February 23rd news release noted that, “RISC 2.0 is a free, web-based platform where organizations can conduct risk assessments by identifying threats, assessing vulnerabilities, determining consequences and criticality, and sharing findings with stakeholders. Currently more than 3,500 health systems are using the RISC Tool. The new cybersecurity module guides users through a series of questions about their policies and practices, scoring responses against the NIST Cybersecurity Framework 2.0 and HHS Cybersecurity Performance Goals.” This resource allows, “facilities, health systems, and coalitions to analyze cyber risk alongside other hazards in one unified tool. Users can complete the cyber module questionnaire independently or in combination with other risk assessments, depending on need.”

(Source: ASPR [News Release](#), 2/23/26)

The FDA has [launched](#) a, “new unified platform for analyzing adverse event reports. This platform — called the FDA Adverse Event Monitoring System (AEMS) — represents a major achievement in the agency’s mission to modernize and provide radical transparency into the safety of regulated products,” according to an agency news release. “With the new system, adverse event reports submitted to the FDA for drugs, biologics, vaccines, cosmetics, and animal food can be displayed in a single streamlined dashboard. In the months ahead, all remaining product centers will begin processing adverse event reports in AEMS. The agency will also migrate historical adverse event data to AEMS, decommission certain legacy systems, and roll out enhanced application program interfaces (APIs) and data analytics tools. By the end of May 2026, AEMS will contain real-time adverse event reports for all FDA-regulated products, consistent with meeting agency obligations not to release individually identifiable patient or consumer information. [Transparency around] adverse event reports submitted by patients, consumers, clinicians, and manufacturers is a critical component of the FDA’s postmarket surveillance capability.” The new system will replace several legacy systems including FAERS (FDA Adverse Event Reporting System) — containing reports for drugs, biologics, cosmetic products, and color additives; VAERS (Vaccine Adverse Event Reporting System) — containing reports for vaccines; and MAUDE (Manufacturer and User Facility Device Experience) — containing reports for medical devices.”

(Source: [FDA New Release](#), 3/11/26) 💧

PEOPLE



Ruchika Goel, MD, MPH, CABP has joined Carter BloodCare as medical director of Research. Previously, she served as Vitalant’s Senior Medical Director of Corporate Medical Affairs and medical director at ImpactLife Blood Center. In addition to joining the Carter BloodCare team, Dr. Goel will continue her practice as a pediatric hematologist/oncologist at Southern Illinois University School of Medicine, where she holds positions as Professor of Internal Medicine and Pediatrics and Endowed Chair for Excellence in Hematologic Disorders. She is also Adjunct Faculty in the Department of Pathology, Division of Transfusion Medicine, School of Medicine at Johns Hopkins University. Her academic background includes a Bachelor of Medicine and Bachelor of Surgery from All India Institute of Medical Sciences in New Delhi; Master’s in Public Health, Epidemiology and Biostatistics from the School of Public Health at the University of North Carolina in Chapel Hill; Residency at the University of Pittsburgh; Hematology/Oncology Fellowship at Johns Hopkins University and the National Institutes of Health’s National Cancer Institute. Dr. Goel completed her Transfusion Medicine Fellowship at New York Presbyterian Hospital, Weill Cornell Medical College, and New York Blood Center.

(Source: Carter BloodCare Announcement, 3/4/26)

Contributed by James Black, Senior Public Relations Specialist at Carter BloodCare 💧



America's Blood Centers
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.

LAST CALL: Register for Part 3 of the ADRP Webinar Series on Planning, Supplementing, and Maximizing Staffing and Production

[Registration](#) is open for part three of ADRP webinar series titled “Doing More with Less: A 3-Part Series on Planning, Supplementing, & Maximizing Staffing and Production!” Part three will take place on March 18th at 1 p.m. EDT and is titled “Production Planning and Readiness: Aligning DR and DS for Efficient Use of Resources.” Speakers include:

- Kaila DiNallo (Versiti); and
- Julie Eaton (Vitalant).

A recording of the webinar series will be available for all registrants. Please [contact us](#) with questions.

Schedule Released for 2026 ADRP Annual Conference – Register Today!

View the [schedule](#) and [register](#) now for the [2026 ADRP Annual Conference](#) in Minneapolis, Minn., May 12th-14th, at the Hyatt Regency Minneapolis. Remember to [book your hotel](#) room by April 10th for the discounted rate.

Hear conference Keynote Speaker [Courtney Clark](#) deliver “The Short Cut: How Strategic Adaptability Outperforms Grit” as she shares insights from her National Goal Resilience Study. Ms. Clark will explore strategies to help individuals and teams avoid burnout, adapt to change, and focus on what truly drives progress. Attendees will learn how to:

- recognize when persistence helps — and when it holds you back;
- increase flexibility during change and uncertainty;
- distinguish between goals and plans, and focus on what matters most; and
- use a simple framework to prioritize competing demands.

Additionally, this conference offers a chance to learn about industry trends, share ideas, and connect with other donor recruitment, donor services, collections, marketing, and communications professionals. Join more than 300 of your peers by participating in pre-conference workshops, attending compelling educational sessions, engaging in roundtable discussions, and exploring an expansive exhibit hall filled with innovative solutions. Seize this extraordinary opportunity to learn, share, and grow within the blood community. Please [contact us](#) with any questions as we look forward to seeing you!

Volunteer to Join An ADRP Committee in 2026!

Don't miss your chance to make an impact as a part of ADRP's global community! Please join your peers and volunteer to [serve](#) on an ADRP Committee or work group. ADRP is seeking individuals like you, who play a vital role in furthering ADRP's mission to educate and empower blood banking professionals worldwide, who are committed to donor recruitment, donor experience, and donor management.

(continued on page 6)

INSIDE ABC (continued from page 5)

ADRP Committees help execute areas of work identified in the ADRP strategic plan in alignment with annual charges provided by the ADRP Advisory Board. Volunteer opportunities for ADRP Committees and work groups include:

- Conference Committee;
- International Outreach Committee;
- Marketing Resources Committee;
- Webinar Committee; or
- Workshop Work Group on Middle Manager Development.

The deadline to apply for a committee or work group is March 18th. Committee terms are for one year. Please [contact us](#) with questions or requests for additional information.

ADRP Trends in Donor Relations Study Is Now Open

ADRP is pleased to announce the launch of the *ADRP Trends in Donor Relations Study*. This survey is a strategic tool for blood centers to use in evaluating the performance of collection and recruitment operations and marketing strategies in comparison to your domestic and international colleagues. ADRP has partnered with a third-party company, [Dynamic Benchmarking](#), to improve the data collection and reporting experience. As always, our top priority is the confidentiality of your data. The information in this report will only be reported in aggregate and in accordance with anti-trust regulations. A key feature of the reporting platform is the ability to view how your operations compare to others using a variety of dynamic filters, including blood center location, collection levels, and employee count. Only centers that participate in the survey will have access to this information. [Complete the survey](#) by April 1st and only submit one response per blood center, so please coordinate your responses accordingly. [Contact us](#) with any questions. ♦

MEMBER NEWS

Héma-Québec recently [announced](#) the opening of its Lévis Donation Center. A March 3rd news release explained that the facility would, “welcome its first donors as of March 10th. This [is] the province’s 13th donation cent[er] and the very first on Québec City’s south shore. Fully dedicated to plasma donations, the new cent[er] will help advance Québec’s objective of achieving greater self-sufficiency in plasma.”

(Source: Héma-Québec [News Release](#), 3/3/26)

Carter BloodCare is [celebrating](#) its 75 anniversary this year. An announcement from the blood center noted that, “[f]or 75 years, Carter BloodCare has been on a mission to save lives by making transfusion possible. On March 6th, 1951, J.K. and Susie Wadley chartered the nonprofit Wadley Research Institute and Blood Bank in Dallas, the genesis of Carter BloodCare. Today, Texas-based Carter BloodCare is one of the state’s largest blood programs. It collects, tests, and distributes more than 450,000 units of blood and blood components to 225 hospitals across 59 counties in North, Central and East Texas each year.”

(Source: Carter BloodCare [Announcement](#), 3/3/26) ♦

GLOBAL NEWS

CBC News, Canada’s national public news and information service, has [published](#) an article reporting that two individuals have died following plasma donation in recent months (October 2025 and January 2026). The news outlets explained that four deaths have been reported to regulators in the past

(continued on page 7)

GLOBAL NEWS (continued from page 6)

decade with three occurring in Manitoba. According to *CBC News*, “[a 22-year old individual] died on Oct. 25 after she went to an appointment at the Grifols Plasma Donation Cent[er] on Taylor Avenue to give plasma, her friends said. Little is known about the other person who died recently in Winnipeg, other than it happened this January after giving plasma at Grifols’ other location, on Innovation Drive.” The article attributed a statement from Grifols explaining that, “an internal review was conducted and ‘based on the information available at this time, we have no reason to believe that there is a correlation between the donors’ passing and plasma donation.’” A spokesperson for Health Canada, the country’s regulatory authority, noted that, “[t]he assessment of the two recent deaths is ongoing, and no link has been made between the plasma collection and the two deaths.” *CBC News* also reported that one of the deaths happened in Quebec, and attributed a statement to, “[a] spokesperson for Héma-Québec — the non-profit that that supplies all blood and other biological products of human origin in Quebec — [said] they have no records of a fatal adverse reaction following a plasma donation.”

(Source: *CBC News*, “[4 people died after giving plasma in the last decade, 3 of them in Manitoba: Health Canada](#), 3/13/26) ◆

ADVANCED THERAPIES NEWS

The U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), Office of Therapeutic Products (OTP) and the Alliance for Regenerative Medicine (ARM) have **announced** that they, “are co-hosting a hybrid workshop on April 9th, titled “Advancing Pediatric Cell and Gene Therapy Clinical Trials.” The event will, “explore the issues surrounding clinical trials for cell and gene therapies (CGTs) in pediatric populations, particularly for diseases where earlier intervention may result in greater therapeutic benefit. This includes conditions that affect both pediatric and adult populations, as well as diseases that occur primarily in children.” The workshop will feature discussions with relevant stakeholders on:

- “Challenges and potential solutions in pediatric clinical trials for CGT products
- Data and information needed to enroll pediatric patients in CGT clinical trials, including interpretations of the prospect of direct benefit
- Appropriate timing to enroll pediatric patients in CGT trials
- Considerations for enrollment of children at presymptomatic and early disease stages.”

Registration is open for both and required for the [virtual](#) and [in-person](#) options.

(Source: FDA [Announcement](#), 3/10/26)

Terumo Blood and Cell Technologies (Terumo BCT) is **launching**, “a new C> Ecosystem Blueprint — a practical, collaborative approach designed to help cell and gene therapy (C>) developers in the Asia-Pacific (APAC) region move from early development to scalable, repeatable delivery.” A company news release noted that, “the C> Ecosystem Blueprint provides a clear map of how critical capabilities, workflows and partnerships must come together — from cell collection and processing through clinical readiness — to simplify complex workflows and support more cost-efficient, scalable C> development and manufacturing. Terumo BCT will be applying the blueprint in collaboration with regional partners and C> developers across multiple real-world use cases, including the CiRA Foundation to co-develop standardized induced pluripotent stem cell (iPSC) workflows; GenScript contributing upstream cell selection and activation technologies and EurekaBio integrating downstream processing — together enabling an integrated, end-to-end CAR-T workflow solution; and KBIOHealth and Advanced

(continued on page 8)

ADVANCED THERAPIES NEWS (continued from page 7)

Cell Therapy and Research Institute, Singapore (ACTRIS) to address regional GMP training and implementation capabilities.”

(Source: Terumo BCT [News Release](#), 3/5/26)

Lonza and Genetix Biotherapeutics, Inc. have [announced](#), “the extension of their long-term commercial manufacturing agreement. Under the expanded agreement, Lonza will expand manufacturing capacity to support growing demand for Genetix’s ZYNTEGLO™, the only FDA-approved gene therapy for pediatric and adult patients with transfusion-dependent beta-thalassemia.”

(Source: Lonza [News Release](#), 3/9/26)

Mass General Brigham recently [received](#), “a \$50 million gift that will shape the future of cancer care and discovery by empowering the next generation of gene and cell therapy research. The gift, made by anonymous donors, will advance clinical research by experts at Mass General Brigham Cancer Institute and throughout the system, to deliver life-changing treatments for patients with cancer and other diseases. [The] gift will invest in physician-scientists who are transforming genes and cells into living treatments and support the recruitment of global leaders in the field. [To further] harness the dedication and talents of Mass General Brigham clinicians and researchers, the gift will also fund clinical trials for emerging gene and cell therapies across multiple diseases, helping to bring promising new treatments to patients as quickly as possible.”

(Source: Mass General Brigham [News Release](#), 3/12/26) ♦

COMPANY NEWS

Hemanext Inc. has [announced](#) that the, “Hemanext ONE® System has received [510\(k\) clearance](#) from the U.S. Food and Drug Administration (FDA) for expanded indications for use in the U.S.” According to a company news release, “[t]he clearance enables U.S. blood establishments to use the Hemanext ONE System to process any AS-3 leukocyte-reduced red blood cells, derived from either whole blood or apheresis, processed with the Hemanext ONE System [which] can now process whole blood-derived or apheresis-derived CP2D/AS-3 leukocyte-reduced RBCs, as well as apheresis-derived ACD-A/AS-3 leukocyte-reduced RBCs.” Hemanext Chief Executive Officer Shane Ray stated in the news release, “[w]e are extremely excited about the recent 510(k) clearance expanding the processing conditions for generating hypoxic red blood cells using Hemanext ONE. This milestone reflects the dedication and persistence of our team and strengthens our ability to work alongside our blood establishment and hospital partners to advance transfusion care. By expanding access to this innovation across the U.S., we are focused on delivering meaningful clinical and economic benefits to hospitals while supporting the availability of high-quality red blood cells for patients who need transfusions.”

(Source: Hemanext Inc., [News Release](#), 3/10/26) ♦



CALENDAR

Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to newsletter@americasblood.org. (For a more detailed announcement in the weekly “Meetings” section of the newsletter, please include program information.)

2026

Mar. 18. **ADRP “Doing More with Less: A 3-Part Series on Planning, Supplementing, & Maximizing Staffing and Production” Webinar Series Part III: Production Planning and Readiness: Aligning DR and DS for Efficient Use of Resources.** [Registration](#) is open. More information is available [here](#).

April 2. **ADRP and Terumo Blood and Cell Technologies Webinar: “Transforming Blood Centers: Reveos Success in the U.S.”** [Registration](#) is open. More information is available [here](#).

April 9. **U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER), Office of Therapeutic Products (OTP) and the Alliance for Regenerative Medicine (ARM) Workshop: “Advancing Pediatric Cell and Gene Therapy Clinical Trials” (Hybrid).** Registration is open and required for both the [virtual](#) and [in-person](#) options. More information is available [here](#).

May 12-14. **2026 ADRP Annual Conference. Minneapolis, Minn.** [Registration](#) is open. More information is available [here](#).

May 20-21. **IPFA/Paul-Ehrlich Institut[e] (PEI) 32nd International Workshop on Surveillance and Screening of Blood-borne Pathogens. Bilbao, Spain.** [Registration](#) is open. More information available [here](#).

June 8-9. **2026 ABC Advocacy Workshop. Washington, D.C.** More information is coming soon.

June 20-24. **International Society of Blood Transfusion (ISBT) 39th International Congress. Kuala Lumpur, Malaysia.** [Registration](#) is open. More information available [here](#).

Oct. 4-7. **Association for Advancing Tissue and Biologics (AATB) Annual Meeting. San Francisco, Calif.** More information available [here](#).

Oct. 17-19. **Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting. Atlanta, Ga.** More information is coming soon.

Nov. 17-20. **American Society for Clinical Pathology (ASCP) and Canadian Association of Pathologists- Association Canadienne des Pathologistes (CAP-ACP) Joint Annual Meeting. Montreal, QC.** [Registration](#) is open. More information available [here](#). 💧

CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: newsletter@americasblood.org

POSITIONS

Director Quality Assurance and Regulatory Affairs (Orlando, FL). OneBlood is seeking an experienced **Director of Quality Assurance & Regulatory Affairs** to lead the strategy, implementation, and oversight of quality and compliance programs across the organization. This role directs departmental operations to ensure adherence to federal and state regulations, licensing, and accreditation standards, while serving as the primary liaison during regulatory inspections. The Director oversees

validation and qualification programs, internal audits, and continuous quality improvement initiatives that support the safety, reliability, and efficiency of blood collection and transfusion services. This position also evaluates emerging technical developments and partners

(continued on page 10)

POSITIONS (continued from 9)

with leadership to strengthen quality systems and operational performance. **Qualifications:** Bachelor's degree in a life science or healthcare field (Master's preferred) and 10+ years of progressive leadership in quality and regulatory affairs, ideally within a blood banking environment. Florida Supervisor's License in Immunohematology, SBB, and ASQ certification preferred. [Apply Here.](#)

Medical Laboratory Scientist, Specialist I/Technologist Specialist I, Certified. ARUP laboratories is looking for a Medical Laboratory Scientist Specialist (MLS/MT) with transfusion medicine experience to join our AABB-accredited Immunohematology Reference Laboratory (IRL). The IRL supports the University of Utah Healthcare as well as clients from around the United States. MLS in the ARUP IRL performs testing that spans from routine type and screens to complex antibody identifications. Many of the employees in the IRL are SBB (Specialty in Blood Banking) certified. The employees have the opportunity to see some of the rarest antibodies currently known in the area of immunohematology. Due to the complexity of this department, we would prefer a candidate who has three (3) years of experience as an MT/MLS in a Transfusion Service. SBB and/or IRL experience are preferred, but not required. Candidate must be willing to participate in on-call rotation of approximately 1/6 weeks and act as backup call 1/6 weeks. Candidate will receive at least six (6) months of training working Monday - Friday, 8:00 AM - 4:30 PM, and then move to a morning shift. Preferred hours would be 9:30 AM - 6:00 PM. We offer exceptional benefits, competitive pay, and beautiful facilities to work in. Prospective candidates may be eligible for applicable relocation assistance. Interested candidates can apply at <http://www.aruplab.com/careers>

Director, Donor Marketing. The Director, Donor Marketing is a pivotal leadership role within New York Blood Center Enterprises (NYBCe), overseeing a team of seasoned marketing professionals tasked with driving donor engagement and donor acquisition across various Blood Operations divisions. Working closely with divisional Donor Recruitment and Collections teams to ensure alignment with overarching marketing strategies. The Director, Donor Marketing operationalizes Enterprise Donor Engagement strategies at the local level, guiding and empowering divisional marketing managers to execute targeted initiatives that meet product and service objectives across all divisions. Reporting directly to the Executive Director, Strategy and Planning, Donor Engagement, this role carries significant responsibility in steering local marketing efforts in line with enterprise goals. Education: BA or master's degree in marketing, communications, or public relations. Experience: Minimum 10 years of demonstrated leadership experience in marketing and/or communications, including at least

seven years of team management. Demonstrated experience managing budgets. Demonstrated experience evaluating media opportunities and buying. Strong organizational and managerial skills, adept at prioritizing assignments and problem-solving within tight constraints. Excellent written and oral presentation skills. Licenses / Certification: Valid Driver's License. Click [here](#) to apply.

Medical Technologist Careers Available! Join One-Blood's healthcare team as a Medical Technologist in the beautiful sunny state of Florida. In this dynamic role, you will perform basic through advanced testing procedures on patient and/or donor samples and interpret results in accordance with regulatory guidelines and organizational policies and procedures. A valid and current Florida Clinical Laboratory Technologist license, as well as a bachelor's degree in a biological science or related scientific field from an accredited college or university, is needed. We offer a comprehensive compensation and benefits package including healthcare, shift differentials, student loan repayment, 403b, and more! To apply and view a complete Job Description of these positions, go to www.oneblood.org and click on the **Careers** tab. One-Blood, Inc. is an Equal Opportunity Employer/Vet/Disability.

Executive Director – Memphis. Vitalant is seeking an exceptional, mission-driven leader to serve as the Executive Director for our Memphis region. This influential role oversees daily operations, community engagement, mobile and fixed-site collections performance, and ensures alignment with organizational strategy and standards. The Executive Director partners closely with regional and enterprise leadership to drive collection success, strengthen customer and donor relationships, and foster a culture grounded in accountability, learning, and collaboration. **We're Looking for a Leader Who Can:** Translate strategy into effective local execution. Inspire and develop high-performing teams. Build strong partnerships across community and stakeholder groups. Drive operational excellence, adaptability, and innovation. This role offers a competitive compensation and total rewards package, including a performance-based bonus plan that recognizes the significance and impact of this position. Interested applicants can apply at <http://www.vitalant.org/careers>

Director of Quality Assurance. Houchin Community Blood Bank is seeking a Director of Quality Assurance to lead our enterprise-wide quality program supporting the collection, processing, testing, and distribution of lifesaving blood products. The Director of QA will provide direct leadership to the Quality Assurance team and drive continuous improvement, regulatory compliance, and inspection readiness across all departments and locations, ensuring alignment with FDA, AABB, CLIA, cGMP, and

(continued on page 11)

POSITIONS (continued from 10)

other regulatory and accrediting standards. Primary responsibilities include leading regulatory, accreditation, and consignee inspections; overseeing internal and external audits; and managing systems for error prevention, detection, investigation, and corrective and preventive actions. The Director of QA will own SOP lifecycle management, document control, equipment qualification and validation, and quality-related training and competency programs, while partnering with executive and operational leadership to support organizational goals and maintain the highest level of product and patient safety. Qualified applicants will have a Bachelor's degree in a life sciences field, with extensive experience in a regulated environment and at least five (5) years in a management role in quality, compliance, or regulatory audit within laboratory, blood services, cell therapy, or healthcare. Strong candidates will bring advanced communication and technical writing skills, proven experience with Quality Management Systems, deviation investigation and CAPA, and personnel training and competency assessment; ASQ CQA and/or SBB certifications are highly desired. We offer many benefits including: Health/Dental/Vision Insurance, Flexible Spending Account, Employee Assistance Program for you and your family, Wellness Program, Company Paid Time Off, and 401K with Company Match. Apply online today at [HCBB Careers](#).

Vice President, Enterprise Laboratory Services (VPELS). Reporting directly to the Chief Operating Officer for Blood and Laboratory Operations, the **Vice President, Enterprise Laboratory Services (VP-ELS)** serves as the senior executive leader responsible for the strategic and operational oversight of Enterprise Laboratory Services across NYBCe. This role leads day-to-day laboratory operations while driving enterprise-wide strategy, financial performance, and operational excellence. The VP-ELS holds full P&L accountability, including revenue and operating margins, and is responsible for developing and managing budgets, implementing business plans, and fostering a high-performance, customer-centric culture. In partnership with Quality, Medical, and Executive Leadership, the VP-ELS will design and execute a forward-looking laboratory testing strategy aligned with NYBCe's mission and evolving customer needs. Qualifications include a bachelor's degree in medical technology or a related field (advanced degree preferred) and a minimum of 15 years of blood banking or comprehensive laboratory experience, including at least five years in progressive leadership roles. Demonstrated experience leading multi-site, multi-state laboratory operations in regulated CLIA and/or cGMP environments is required, along with direct experience working with the FDA, CLIA, and State Departments of Health. A proven track record managing regulatory inspections and driving CAPA to successful closure is essential. Click [here](#) to apply.

Director of Finance. Sheppard Community Blood Center in Augusta, Ga. is seeking an experienced Director of Finance to lead the organization's financial, operational, and administrative activities. This executive-level role is responsible for financial stewardship, supply-chain management, operational efficiency, risk mitigation, and supporting organizational growth. The ideal candidate will be an analytical thinker with strong leadership skills and a commitment to excellence. Sheppard offers a competitive salary, generous PTO, relocation expense reimbursement, and a 403(b) retirement plan with a 9 percent match. Qualified candidates can apply at: <https://sheppardblood.org/>.

Director-Immunohematology Reference Laboratory. The Director of Immunohematology Reference Laboratories oversees clinical laboratory operations with a focus on technical excellence, timely result delivery, client satisfaction, quality assurance, and operational efficiency. The role ensures proactive communication with clients and stakeholders, addresses concerns promptly, and promotes a service-oriented culture. It also ensures ongoing compliance with CLIA, NYS-DOH, AABB, and FDA standards, leads proficiency testing, and implements corrective actions. Operational duties include managing staffing, budgets, SOPs, equipment, and safety while fostering staff engagement and development. Education: Bachelor's degree in clinical laboratory science, Medical Technologist, Immunology, or a related field. Experience: Six or more years of relevant technical and service-related industry experience in a high-complexity laboratory or blood bank setting with four or more years of supervisory/managerial experience in a laboratory setting. Licenses / Certification: New York State Clinical laboratory technologist license required. SBB certification is required. Click [here](#) to apply.

Manager-Immunohematology Reference Laboratory. This position is responsible for providing leadership and direction for the daily operations of the Immunohematology laboratory. The primary duties include overseeing the clinical laboratory testing procedures, timely result delivery, client satisfaction, and supervision of laboratory staff. As defined by CLIA/NYSDOH, this position is responsible for pre-analytic, analytic procedures, maintaining records of tests, and reporting test results in a high complexity laboratory. This position performs only those tests that are authorized by the CLIA/NYSDOH laboratory director and performs only those tests that require a degree of skill commensurate with the individual's education, training or experience, and technical abilities. Education: Bachelor's degree in clinical laboratory science, Medical Technologist, Immunohematology, or a related field. Experience: Six or more years of relevant technical and service-related industry experience in a high-complexity laboratory or

(continued on page 12)

POSITIONS (continued from 11)

blood bank setting with two or more years of supervisory/managerial experience in a laboratory setting. Licenses / Certification: New York State Clinical laboratory technologist license required. SBB certification is preferred. Click [here](#) to apply. 💧